{"component": "definition", "props": {"groups": [{"samples": [{"hash": "8BsKfXNZrcS", "uri": "/contracts/8BsKfXNZrcS#approval-milestone", "label": "License and Collaborative Research Agreement (Intellia Therapeutics, Inc.)", "score": 31.3429164886, "published": true}, {"hash": "e4QAV4LWh79", "uri": "/contracts/e4QAV4LWh79#approval-milestone", "label": "License and Collaborative Research Agreement (Intellia Therapeutics, Inc.)", "score": 26.3408622742, "published": true}, {"hash": "IfnetTrdxl", "uri": "/contracts/IfnetTrdxl#approval-milestone", "label": "License and Collaborative Research Agreement (Intellia Therapeutics, Inc.)", "score": 26.2970561981, "published": true}], "snippet": "has the meaning set forth in Section 7.3.3.", "size": 4, "snippet_links": [{"key": "section-733", "type": "clause", "offset": [29, 42]}], "hash": "8c5cc9f5332cb4cf10ed8519ba2cf2f5", "id": 1}, {"samples": [{"hash": "j4r7APQsUpe", "uri": "/contracts/j4r7APQsUpe#approval-milestone", "label": "Contingent Value Rights Agreement (Wright Medical Group Inc)", "score": 24.1622180939, "published": true}, {"hash": "aYHUAa2t4BB", "uri": "/contracts/aYHUAa2t4BB#approval-milestone", "label": "Contingent Value Rights Agreement (Wright Medical Group Inc)", "score": 24.1622180939, "published": true}, {"hash": "fC1sMkSgt78", "uri": "/contracts/fC1sMkSgt78#approval-milestone", "label": "Contingent Value Rights Agreement (Biomimetic Therapeutics, Inc.)", "score": 23.8829574585, "published": true}], "snippet": "means receipt by the Company or one of its Affiliates of the first FDA Approval of AUGMENT Bone Graft based on the AUGMENT PMA.", "size": 4, "snippet_links": [{"key": "by-the-company", "type": "clause", "offset": [14, 28]}, {"key": "approval-of", "type": "clause", "offset": [71, 82]}, {"key": "based-on", "type": "definition", "offset": [102, 110]}], "hash": "4ebd5244c037d53e298c7b0212d62e4b", "id": 2}, {"samples": [{"hash": "bWlvoWSewOq", "uri": "/contracts/bWlvoWSewOq#approval-milestone", "label": "Loan and Security Agreement (Tricida, Inc.)", "score": 31.3791923523, "published": true}, {"hash": "2fBaPYuJ6zl", "uri": "/contracts/2fBaPYuJ6zl#approval-milestone", "label": "Loan and Security Agreement (Tricida, Inc.)", "score": 30.2347698212, "published": true}, {"hash": "6j1VEAKBCGi", "uri": "https://ir.tricida.com/static-files/556d7c02-1275-40b4-879c-c5d065030e5d", "label": "ir.tricida.com", "score": 10.1895961761, "published": false}], "snippet": "means on or before December 15, 2020, Borrower shall have obtained final approval for the NDA for TRC101 from the FDA, subject to verification by Agent (including supporting documentation requested by Agent).", "size": 4, "snippet_links": [{"key": "before-december", "type": "clause", "offset": [12, 27]}, {"key": "borrower-shall", "type": "clause", "offset": [38, 52]}, {"key": "final-approval", "type": "clause", "offset": [67, 81]}, {"key": "the-fda", "type": "clause", "offset": [110, 117]}, {"key": "subject-to", "type": "clause", "offset": [119, 129]}, {"key": "by-agent", "type": "clause", "offset": [143, 151]}, {"key": "supporting-documentation", "type": "definition", "offset": [163, 187]}, {"key": "requested-by", "type": "definition", "offset": [188, 200]}], "hash": "53f20e45a5e1823fc9d44272e4caaf27", "id": 3}, {"samples": [{"hash": "1nqlt12hNA3", "uri": "/contracts/1nqlt12hNA3#approval-milestone", "label": "Term Loan Agreement (T2 Biosystems, Inc.)", "score": 29.2108154297, "published": true}, {"hash": "5k272VPYO2H", "uri": "/contracts/5k272VPYO2H#approval-milestone", "label": "Term Loan Agreement (T2 Biosystems, Inc.)", "score": 28.200548172, "published": true}, {"hash": "jG9tPAxNg9y", "uri": "http://www.annualreports.com/HostedData/AnnualReportArchive/T/NASDAQ_TTOO_2016.pdf", "label": "www.annualreports.com", "score": 10.1704311371, "published": false}], "snippet": "means 510(k) clearance for the marketing of T2Bacteria\u2122 by the United States Food and Drug Administration on or prior to April 30, 2018.", "size": 3, "snippet_links": [{"key": "the-united-states", "type": "definition", "offset": [59, 76]}, {"key": "food-and-drug-administration", "type": "definition", "offset": [77, 105]}, {"key": "prior-to", "type": "definition", "offset": [112, 120]}], "hash": "40116d0139bb5c80c291412515e2195b", "id": 4}, {"samples": [{"hash": "Hc5YEJWAco", "uri": "/contracts/Hc5YEJWAco#approval-milestone", "label": "Contingent Value Rights Agreement (Genzyme Corp)", "score": 22.1252574921, "published": true}, {"hash": "8uxRevSgB8d", "uri": "/contracts/8uxRevSgB8d#approval-milestone", "label": "Merger Agreement (Genzyme Corp)", "score": 22.1252574921, "published": true}, {"hash": "7nZBhMTm2A0", "uri": "/contracts/7nZBhMTm2A0#approval-milestone", "label": "Contingent Value Rights Agreement (Sanofi-Aventis)", "score": 22.1252574921, "published": true}], "snippet": "means receipt by the Company or one of its Affiliates, on or before March 31, 2014, of the FDA Approval of alemtuzumab for treatment of multiple sclerosis.", "size": 3, "snippet_links": [{"key": "by-the-company", "type": "clause", "offset": [14, 28]}, {"key": "approval-of", "type": "clause", "offset": [95, 106]}, {"key": "treatment-of", "type": "definition", "offset": [123, 135]}, {"key": "multiple-sclerosis", "type": "clause", "offset": [136, 154]}], "hash": "4471e63501e981edb9e95e173c485840", "id": 5}, {"samples": [{"hash": "e6V0gj2ji10", "uri": "/contracts/e6V0gj2ji10#approval-milestone", "label": "Collaboration and License Agreement (Fulcrum Therapeutics, Inc.)", "score": 31.1738529205, "published": true}], "snippet": "has the meaning set forth in Section 6.2.2(a).", "size": 3, "snippet_links": [], "hash": "ad41ce16634b1415a6ccaa4c73363c54", "id": 6}, {"samples": [{"hash": "8syds1Ju9VX", "uri": "/contracts/8syds1Ju9VX#approval-milestone", "label": "Loan and Security Agreement (Savara Inc)", "score": 37.1943855286, "published": true}, {"hash": "5kIvoxJG8lT", "uri": "/contracts/5kIvoxJG8lT#approval-milestone", "label": "Loan and Security Agreement (Savara Inc)", "score": 36.3620796204, "published": true}], "snippet": "Agent\u2019s receipt of evidence in form and substance satisfactory to Agent that (a) no Default or Event of Default shall have occurred and (b) Borrower has received FDA approval for molgramostim for the treatment of aPAP with a label that is consistent in all material respects with that sought in Borrower\u2019s Biologics License Application for molgramostim, subject to verification by Agent (including supporting documentation requested by Agent).", "size": 2, "snippet_links": [{"key": "receipt-of", "type": "clause", "offset": [8, 18]}, {"key": "form-and-substance", "type": "clause", "offset": [31, 49]}, {"key": "default-shall", "type": "definition", "offset": [104, 117]}, {"key": "fda-approval", "type": "definition", "offset": [162, 174]}, {"key": "treatment-of", "type": "definition", "offset": [200, 212]}, {"key": "in-all-material-respects", "type": "definition", "offset": [250, 274]}, {"key": "biologics-license-application", "type": "definition", "offset": [306, 335]}, {"key": "subject-to", "type": "clause", "offset": [354, 364]}, {"key": "by-agent", "type": "clause", "offset": [378, 386]}, {"key": "supporting-documentation", "type": "definition", "offset": [398, 422]}, {"key": "requested-by", "type": "definition", "offset": [423, 435]}], "hash": "42bbbddf503d743cb161fb4c2ac5c646", "id": 7}, {"samples": [{"hash": "ln5nYUVzp04", "uri": "/contracts/ln5nYUVzp04#approval-milestone", "label": "Loan and Security Agreement (Tricida, Inc.)", "score": 29.421628952, "published": true}, {"hash": "dgPNUK6PRei", "uri": "/contracts/dgPNUK6PRei#approval-milestone", "label": "Loan and Security Agreement (Tricida, Inc.)", "score": 29.3641338348, "published": true}], "snippet": "means satisfaction of each of the following events: (a) no Event of Default shall have occurred and be continuing and (b) on or before December 15, 2020, Borrower shall have obtained final approval for the NDA for TRC101 from the FDA, subject to verification by Agent (including supporting documentation requested by Agent).", "size": 2, "snippet_links": [{"key": "satisfaction-of", "type": "clause", "offset": [6, 21]}, {"key": "default-shall", "type": "definition", "offset": [68, 81]}, {"key": "before-december", "type": "clause", "offset": [128, 143]}, {"key": "borrower-shall", "type": "clause", "offset": [154, 168]}, {"key": "final-approval", "type": "clause", "offset": [183, 197]}, {"key": "the-fda", "type": "clause", "offset": [226, 233]}, {"key": "subject-to", "type": "clause", "offset": [235, 245]}, {"key": "by-agent", "type": "clause", "offset": [259, 267]}, {"key": "supporting-documentation", "type": "definition", "offset": [279, 303]}, {"key": "requested-by", "type": "definition", "offset": [304, 316]}], "hash": "92d6d8994e3dfc79cdf48014b7dafd58", "id": 8}, {"samples": [{"hash": "koN8JpH8Cn5", "uri": "/contracts/koN8JpH8Cn5#approval-milestone", "label": "Loan and Security Agreement (Kura Oncology, Inc.)", "score": 33.8377838135, "published": true}, {"hash": "72HdF4lEX25", "uri": "https://ir.kuraoncology.com/static-files/61c6ee86-950a-4b41-b6b6-73dcedce78e6", "label": "ir.kuraoncology.com", "score": 19.2588233948, "published": false}], "snippet": "means Borrower shall have obtained approval of the NDA for Ziftomenib from the FDA, with an approved label that is generally consistent with the label sought in Borrower\u2019s NDA, subject to reasonable verification by Agent (including any supporting documentation requested by Agent).", "size": 2, "snippet_links": [{"key": "borrower-shall", "type": "clause", "offset": [6, 20]}, {"key": "approval-of", "type": "clause", "offset": [35, 46]}, {"key": "the-fda", "type": "clause", "offset": [75, 82]}, {"key": "approved-label", "type": "definition", "offset": [92, 106]}, {"key": "consistent-with-the", "type": "clause", "offset": [125, 144]}, {"key": "subject-to", "type": "clause", "offset": [177, 187]}, {"key": "reasonable-verification", "type": "clause", "offset": [188, 211]}, {"key": "by-agent", "type": "clause", "offset": [212, 220]}, {"key": "supporting-documentation", "type": "definition", "offset": [236, 260]}, {"key": "requested-by", "type": "definition", "offset": [261, 273]}], "hash": "90cf2f11e0802803103450400ff99489", "id": 9}, {"samples": [{"hash": "c7wKh0Y95yP", "uri": "/contracts/c7wKh0Y95yP#approval-milestone", "label": "Development, License and Commercialization Agreement (Idenix Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "5qngnGWWkGT", "uri": "/contracts/5qngnGWWkGT#approval-milestone", "label": "Development, License and Commercialization Agreement (Idenix Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet": "Percentage shall have the meaning assigned to it in Section 8.8(c).", "size": 2, "snippet_links": [], "hash": "576796fb37a61393ba81ac148ed5c2c4", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIbYXBwcm92YWwtbWlsZXN0b25lIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "has the meaning set forth in Section 7.3.3.", "size": 56, "title": "Approval Milestone", "id": "approval-milestone", "examples": ["Notwithstanding anything to the contrary in this Agreement, no <strong>Approval Milestone</strong> Payment that constitutes nonqualified deferred compensation subject to Section 409A of the Code shall be allocated or paid in respect of any Company Option or Company RSU, except to the extent permissible under Treasury Regulation Section 1.409A-3(i)(5)(iv)(A).", "If any <strong>Approval Milestone</strong> Payment has not been paid immediately prior to the date on which such <strong>Approval Milestone</strong> Payment would otherwise escheat to or become the property of any Governmental Body, any such <strong>Approval Milestone</strong> Payment will, to the extent permitted by applicable Legal Requirement, become the property of Parent, free and clear of all claims or interest of any Person previously entitled thereto.", "Notwithstanding the foregoing, in no event shall Parent be required to pay any <strong>Approval Milestone</strong> Payment more than once."], "related": [["milestone-1", "Milestone 1", "Milestone 1"], ["development-milestone", "Development Milestone", "Development Milestone"], ["development-milestone-event", "Development Milestone Event", "Development Milestone Event"], ["milestone-date", "Milestone Date", "Milestone Date"], ["milestone-2", "Milestone 2", "Milestone 2"]], "related_snippets": [], "updated": "2026-05-13T04:23:52+00:00"}, "json": true, "cursor": ""}}